Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease

NCT05357989 is registered in ClinicalTrials.gov with Annovis Bio Inc. as lead sponsor.

NCT NCT05357989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05357989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Lead sponsor
Annovis Bio Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 3, 2022
Completion date
December 4, 2023
Enrollment
523 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease, idiopathic